Elizabeth Kavaler, MD
Urology · New York, NYNPI 1386695781
Payments from drug & device makers
Across 292 payments — averaging $122.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Astellas Pharma US Inc$9K
- Boston Scientific$3K
- Coloplast$2K
- Axonics, Inc.$564
- Caldera Medical, Inc$481
- plus $2K from 24 others
Across 1 payment — averaging $355.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$355
What the payments were for
- Consulting fees$3751%
- Speaking & faculty fees$22,24962%
- Travel & lodging$1,1333%
- Food & beverage$11,77633%
- Education$2431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $18,393 |
| Astellas Pharma US Inc | 65 | $8,835 |
| Boston Scientific | 40 | $3,177 |
| Coloplast | 24 | $2,461 |
| Axonics, Inc. | 6 | $564 |
| Caldera Medical, Inc | 5 | $481 |
| Femselect Inc. | 2 | $401 |
| Medtronic(2 entities) | 9 | $282 |
| Endo Pharmaceuticals Inc. | 12 | $253 |
| Hollister Incorporated | 8 | $169 |
| Pfizer | 4 | $99 |
| ABC Home Medical Supply, Inc. | 3 | $84 |
| Antares Pharma, Inc. | 3 | $80 |
| AMAG Pharmaceuticals, Inc. | 3 | $58 |
| Acerus Pharmaceuticals Corporation | 3 | $54 |
| Renovia Inc | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 2 | $50 |
| Contura, Inc. | 1 | $40 |
| Merck | 2 | $40 |
| Millicent US Inc | 1 | $24 |
| Convatec Inc. | 1 | $21 |
| Dentsply IH AB | 1 | $20 |
| Neotract Inc. | 1 | $20 |
| 180 Medical, Inc. | 1 | $20 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Urogen Pharma, Inc. | 1 | $19 |
| Dentsply IH Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Rochester Medical Corporation | 1 | $14 |
| Escala Medical Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$16,635
- MYRBETRIQ$7,187
- ALTIS$1,949
- SOLYX$1,256
- Solyx SIS System$451
- Axonics$409
- EnPlace$401
- Bulkamid$350
- UPSYLON$283
- Desara$258
- SOLYX BLUE$145
- GENERAL PELVIC ORGAN PROLAPSE$140
- Veozah$125
- LithoVue$120
- BOTOX COSMETIC$117
How this compares
$35,776 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 881 | $573,277 |
| GemtesaVibegron | 72 | $43,475 |
| Mirabegron ErMirabegron | 59 | $36,071 |
| Estradiol | 371 | $29,654 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 555 | $21,413 |
| BotoxOnabotulinumtoxina | 11 | $14,089 |
| NitrofurantoinNitrofurantoin Macrocrystal | 433 | $13,936 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 796 | $9,134 |
| PremarinEstrogens, Conjugated | 23 | $8,355 |
| Solifenacin Succinate | 258 | $8,018 |
| Oxybutynin Chloride ErOxybutynin Chloride | 293 | $5,949 |
| Fosfomycin Tromethamine | 32 | $5,626 |
| Tolterodine Tartrate ErTolterodine Tartrate | 90 | $4,801 |
| Methenamine Hippurate | 53 | $3,172 |
| Clobetasol Propionate | 34 | $2,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $8,835 | $573,277881 claims |
| AbbVieBotox | $18,393 | $14,08911 claims |
| PfizerPremarin | $99 | $8,35523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 urology providers in New York.
Other urology in New York
- Guarionex DecastroNew York$5.7M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Ashutosh TewariNew York$2.5M
- Bilal ChughtaiNew York$1.5M
- Nils Peter WiklundNew York$1M
- Herbert LeporNew York$823K
- Christopher AndersonNew York$785K
- Katie MurrayNew York$776K
- John SfakianosNew York$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.